{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:12:27Z","timestamp":1785510747714,"version":"3.56.0"},"reference-count":87,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hidradenitis suppurativa (HS) is a chronic, debilitating inflammatory skin disease with substantial quality\u2010of\u2010life impact. Accurate measurement of treatment success requires validated instruments capturing both physician\u2010assessed disease activity and patient\u2010reported symptom burden. Despite an expanding toolkit, consensus on defining remission, optimal control, resolution and progression remains elusive. This review provides a comprehensive overview of key clinician\u2010 and patient\u2010reported outcome measures in HS, evaluates their psychometric properties and critically addresses minimal clinically important difference, remission, optimal control, resolution and progression. The emerging role of tissue damage, fibrosis assessment, imaging and molecular pathology in redefining treatment success is also discussed. A narrative literature review was conducted via systematic PubMed and MEDLINE searches through March 2026, with emphasis on publications from the EHSF, the HiSTORIC consortium, the Global VOICE project, and recent clinical trial data. HiSCR has been the most widely used primary endpoint but is limited by its exclusion of patients with fewer than three abscess\u2010nodule lesions and inability to capture tunnel improvement. The IHS4 is a robust dynamic scoring system incorporating draining tunnels with fourfold weighting; its derivative IHS4\u201055 provides a clinically meaningful response threshold regardless of baseline lesion count. HS\u2010IGA demonstrates high test\u2013retest reliability. Among patient\u2010reported outcomes, HiSQOL is the preferred HS\u2010specific quality\u2010of\u2010life instrument (validated MID: 20\u201321 points), while DLQI remains the most used non\u2010specific tool. The Pain Index effectively evaluates nociceptive pain. Formal definitions of remission, optimal control and progression are being developed through the HiSTORIC treat\u2010to\u2010target initiative. Ultrasound\u2010based fibrosis grading and ultra\u2010high\u2010frequency imaging reveal clinically underscored tissue damage; long\u2010wave infrared thermography may serve as a reproducible inflammatory biomarker. Optimizing HS outcomes requires integration of dynamic physician\u2010reported scores, HS\u2010specific patient\u2010reported outcomes and emerging tissue damage and inflammation metrics. Consensus definitions for remission, minimal disease activity and progression represent the next frontier in HS management.<\/jats:p>","DOI":"10.1111\/jdv.70635","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:54:19Z","timestamp":1785509659000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Measuring success in\n                    <scp>HS<\/scp>\n                    treatment from the physician's and the patient's perspective"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0920-9092","authenticated-orcid":false,"given":"Georgios","family":"Nikolakis","sequence":"first","affiliation":[{"name":"Department of Dermatology University of Basel  Basel Switzerland"},{"name":"Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg  Neuruppin Germany"},{"name":"European Hidradenitis Suppurativa Foundation e.V.  Dessau Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Arenbergerova","sequence":"additional","affiliation":[{"name":"Department of Dermatovenerology, Third Faculty of Medicine Charles University and University Hospital Kralovske Vinohrady  Prague Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeljko","family":"Mijuskovic","sequence":"additional","affiliation":[{"name":"Dermatologika Clinic  Belgrade Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoxi","family":"Wang","sequence":"additional","affiliation":[{"name":"European Hidradenitis Suppurativa Foundation e.V.  Dessau Germany"},{"name":"Department of Dermatology The Plastic Surgery Hospital of CAMS and PUMC  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos C.","family":"Zouboulis","sequence":"additional","affiliation":[{"name":"Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg  Neuruppin Germany"},{"name":"European Hidradenitis Suppurativa Foundation e.V.  Dessau Germany"},{"name":"Department of Dermatology, Venereology and Allergology Universitaesklinikum Ruppin\u2010Brandenburg  Neuruppin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"issue":"12","key":"e_1_2_15_2_1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/exd.14214","article-title":"What causes hidradenitis suppurativa\u2009?\u201415\u2009years after","volume":"29","author":"Zouboulis CC","year":"2020","journal-title":"Exp Dermatol"},{"issue":"8","key":"e_1_2_15_3_1","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jamadermatol.2021.1677","article-title":"Prevalence of hidradenitis suppurativa: a systematic review and meta\u2010regression study","volume":"157","author":"Jfri AH","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"6","key":"e_1_2_15_4_1","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/bjd.19435","article-title":"The epidemiology of hidradenitis suppurativa","volume":"183","author":"Ingram JR","year":"2020","journal-title":"Br J Dermatol"},{"issue":"10","key":"e_1_2_15_5_1","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/jamadermatol.2025.2373","article-title":"Prevalence of hidradenitis Suppurativa","volume":"161","author":"Bouazzi D","year":"2025","journal-title":"JAMA Dermatol"},{"key":"e_1_2_15_6_1","doi-asserted-by":"crossref","unstructured":"KrajewskiPK Matusiak\u0141 vonStebutE SchultheisM KirschnerU NikolakisG et\u00a0al.Quality\u2010of\u2010life impairment among patients with hidradenitis suppurativa: a cross\u2010sectional study of 1795 patients.2021;11(1):1\u20139.https:\/\/doi.org\/10.3390\/life11010034","DOI":"10.3390\/life11010034"},{"issue":"2","key":"e_1_2_15_7_1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jaad.2019.06.1301","article-title":"Evaluating patients' unmet needs in hidradenitis suppurativa: results from the global survey of impact and healthcare needs (VOICE) project","volume":"82","author":"Garg A","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_15_8_1","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/jdv.20472","article-title":"European S2k guidelines for hidradenitis suppurativa\/acne inversa part 2: treatment","volume":"39","author":"Zouboulis CC","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10443","key":"e_1_2_15_9_1","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate\u2010to\u2010severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48\u2010week, randomised, double\u2010blind, placebo\u2010controlled, multicentre phase 3 trials","volume":"403","author":"Kimball AB","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"e_1_2_15_10_1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball AB","year":"2016","journal-title":"N Engl J Med"},{"issue":"10378","key":"e_1_2_15_11_1","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate\u2010to\u2010severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo\u2010controlled, double\u2010blind phase 3 trials","volume":"401","author":"Kimball AB","year":"2023","journal-title":"Lancet"},{"issue":"6007","key":"e_1_2_15_12_1","doi-asserted-by":"crossref","DOI":"10.1126\/science.1196284","article-title":"\u0393\u2010secretase gene mutations in familial acne Inversa","volume":"330","author":"Wang B","year":"2010","journal-title":"Science"},{"issue":"5","key":"e_1_2_15_13_1","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jaad.2015.07.041","article-title":"Bacteriology of hidradenitis suppurativa\/acne inversa: a review","volume":"73","author":"Nikolakis G","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"e_1_2_15_14_1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2340\/00015555-2591","article-title":"Bacterial colonization in hidradenitis suppurativa\/acne inversa: a cross\u2010sectional study of 50 patients and review of the literature","volume":"97","author":"Nikolakis G","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"e_1_2_15_15_1","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s00105-021-04853-x","article-title":"Pathogenesis of hidradenitis suppurativa\/acne inversa","volume":"72","author":"Nikolakis G","year":"2021","journal-title":"Hautarzt"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.04.021"},{"issue":"4","key":"e_1_2_15_17_1","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/jdv.16147","article-title":"Alterations in innate immunity and epithelial cell differentiation are the molecular pillars of hidradenitis suppurativa","volume":"34","author":"Zouboulis CC","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"e_1_2_15_18_1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1159\/000509873","article-title":"Phenotypes and pathophysiology of syndromic hidradenitis suppurativa: different faces of the same disease? A systematic review","volume":"237","author":"Nikolakis G","year":"2021","journal-title":"Dermatology"},{"issue":"2","key":"e_1_2_15_19_1","doi-asserted-by":"crossref","first-page":"T213","DOI":"10.1016\/j.ad.2023.11.012","article-title":"[Translated article] can we improve prognosis in hidradenitis suppurativa? Identifying patients in the window of opportunity","volume":"115","author":"Melgosa Ramos FJ","year":"2024","journal-title":"Actas Dermosifiliogr"},{"issue":"2","key":"e_1_2_15_20_1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40257-026-01011-8","article-title":"Defining moderate disease and progression in hidradenitis suppurativa: an expert framework to unlock the window of opportunity for prompt treatment","volume":"27","author":"Martorell A","year":"2026","journal-title":"Am J Clin Dermatol"},{"key":"e_1_2_15_21_1","unstructured":"NikolakisG AlpsoyE AnzengruberF AugustinM BecharaFG BecherelP et\u00a0al.Delphi consensus: first\u2010line use of biologics and small molecules in hidradenitis suppurativa.J Eur Acad Dermatol Venereol.https:\/\/doi.org\/10.1111\/jdv.702642026."},{"key":"e_1_2_15_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70118"},{"issue":"1","key":"e_1_2_15_23_1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamadermatol.2025.4700","article-title":"Hidradenitis suppurativa remission and progression in a community setting","volume":"162","author":"Andersen RK","year":"2026","journal-title":"JAMA Dermatol"},{"issue":"5","key":"e_1_2_15_24_1","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/bjd\/ljag041","article-title":"Treat\u2010to\u2010target: optimizing outcomes for hidradenitis suppurativa","volume":"194","author":"Ingram JR","year":"2026","journal-title":"Br J Dermatol"},{"issue":"3","key":"e_1_2_15_25_1","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjd.16672","article-title":"A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process","volume":"179","author":"Thorlacius L","year":"2018","journal-title":"Br J Dermatol"},{"key":"e_1_2_15_26_1","first-page":"729","volume-title":"Dermatologic surgery","author":"Hurley H","year":"1989"},{"key":"e_1_2_15_27_1","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1145152","article-title":"Overview and comparison of the clinical scores in hidradenitis suppurativa: a real\u2010life clinical data","volume":"10","author":"Daoud M","year":"2023","journal-title":"Front Med"},{"issue":"3","key":"e_1_2_15_28_1","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/bjd.17716","article-title":"Inter\u2010rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa","volume":"181","author":"Thorlacius L","year":"2019","journal-title":"Br J Dermatol"},{"issue":"2","key":"e_1_2_15_29_1","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1111\/jdv.19525","article-title":"The inter\u2010rater reliability of IHS4 corroborates its aptitude as primary outcome measurement instrument for large clinical studies in hidradenitis suppurativa","volume":"38","author":"Zouboulis CC","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_15_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17588"},{"issue":"11","key":"e_1_2_15_31_1","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1111\/jdv.15710","article-title":"Ultrasound as a diagnostic and management tool in hidradenitis suppurativa patients: a multicentre study","volume":"33","author":"Martorell A","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"e_1_2_15_32_1","doi-asserted-by":"crossref","first-page":"306","DOI":"10.5114\/ada.2025.151138","article-title":"High\u2010frequency ultrasound in the diagnosis of hidradenitis suppurativa: experience from the Bulgarian HS expert Centre","volume":"42","author":"Poterov G","year":"2025","journal-title":"Postepy Dermatol Alergol"},{"issue":"6","key":"e_1_2_15_33_1","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/ddg.15412","article-title":"S2k guideline for the treatment of hidradenitis suppurativa\/acne inversa \u2013 short version","volume":"22","author":"Zouboulis CC","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_15_34_1","doi-asserted-by":"publisher","DOI":"10.1055\/a\u20102225\u20107983"},{"issue":"1","key":"e_1_2_15_35_1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1365-2133.2003.05390.x","article-title":"Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa","volume":"149","author":"Sartorius K","year":"2003","journal-title":"Br J Dermatol"},{"issue":"4","key":"e_1_2_15_36_1","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1365-2133.2009.09198.x","article-title":"Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity","volume":"161","author":"Sartorius K","year":"2009","journal-title":"Br J Dermatol"},{"issue":"5","key":"e_1_2_15_37_1","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/bjd.19565","article-title":"Hidradenitis suppurativa area and severity index revised (HASI\u2010R): psychometric property assessment*","volume":"184","author":"Goldfarb N","year":"2021","journal-title":"Br J Dermatol"},{"issue":"1","key":"e_1_2_15_38_1","first-page":"240","article-title":"Hidradenitis suppurativa area and severity index (HASI): a pilot study to develop a novel instrument to measure the physical signs of hidradenitis suppurativa","volume":"182","author":"Goldfarb N","year":"2020","journal-title":"Br J Dermatol"},{"issue":"6","key":"e_1_2_15_39_1","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/jdv.13216","article-title":"HiSCR (hidradenitis suppurativa clinical response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo\u2010controlled portion of a phase 2 adalimumab study","volume":"30","author":"Kimball AB","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"e_1_2_15_40_1","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial","volume":"157","author":"Kimball AB","year":"2012","journal-title":"Ann Intern Med"},{"issue":"10","key":"e_1_2_15_41_1","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2340\/00015555-3012","article-title":"Achieving hidradenitis suppurativa response score is associated with significant improvement in clinical and patient\u2010reported outcomes: post hoc analysis of pooled data from PIONEER I and II","volume":"98","author":"Kimball AB","year":"2018","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"e_1_2_15_42_1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/exd.14609","article-title":"New treatments and new assessment instruments for hidradenitis suppurativa","volume":"31","author":"Straalen KR","year":"2022","journal-title":"Exp Dermatol"},{"issue":"3","key":"e_1_2_15_43_1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/bjd\/ljad375","article-title":"Addressing high placebo response rates in randomized clinical trials for hidradenitis suppurativa","volume":"190","author":"Garg A","year":"2024","journal-title":"Br J Dermatol"},{"key":"e_1_2_15_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15748"},{"issue":"1","key":"e_1_2_15_45_1","article-title":"Pain in hidradenitis suppurativa: a cross\u2010sectional study of 1795 patients","volume":"101","author":"Krajewski PK","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"e_1_2_15_46_1","first-page":"e496","article-title":"International hidradenitis Suppurativa severity scoring system (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging: a post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab","volume":"38","author":"Zouboulis CC","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"e_1_2_15_47_1","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/jdv.20369","article-title":"Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the international hidradenitis Suppurativa severity score system (IHS4): a post hoc analysis of the SUNSHINE and SUNRISE trials","volume":"39","author":"Zouboulis CC","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_15_48_1","unstructured":"TzellosT Giamarellos\u2010BourboulisEJ vanStraalenKR MartorellA KirbyB AlaviA et\u00a0al.Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: results from BE HEARD I and II.J Eur Acad Dermatol Venereol. Available from:https:\/\/pubmed.ncbi.nlm.nih.gov\/41689425\/2026."},{"issue":"4","key":"e_1_2_15_49_1","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/bjd.17982","article-title":"Inter\u2010rater and intrarater agreement and reliability in clinical staging of hidradenitis suppurativa\/acne inversa","volume":"181","author":"Zouboulis CC","year":"2019","journal-title":"Br J Dermatol"},{"issue":"3","key":"e_1_2_15_50_1","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1159\/000535867","article-title":"Viewpoint on the evaluation of severity and treatment effects in mild hidradenitis suppurativa: the cumulative IHS4","volume":"240","author":"Van Der Zee HH","year":"2024","journal-title":"Dermatology"},{"issue":"6","key":"e_1_2_15_51_1","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/bjd.19798","article-title":"Pain index: a new prospective hidradenitis suppurativa patient\u2010reported outcome measure instrument","volume":"184","author":"Zouboulis CC","year":"2021","journal-title":"Br J Dermatol"},{"issue":"2","key":"e_1_2_15_52_1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/jdv.18632","article-title":"Development and validation of IHS4\u201055, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa","volume":"37","author":"Tzellos T","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"e_1_2_15_53_1","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1159\/000528968","article-title":"External validation of the IHS4\u201055 in a European antibiotic\u2010treated hidradenitis Suppurativa cohort","volume":"239","author":"Straalen KR","year":"2023","journal-title":"Dermatology"},{"issue":"2","key":"e_1_2_15_54_1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/bjd.21236","article-title":"Development and initial validation of the HS\u2010IGA: a novel hidradenitis suppurativa\u2010specific investigator global assessment for use in interventional trials","volume":"187","author":"Garg A","year":"2022","journal-title":"Br J Dermatol"},{"issue":"10","key":"e_1_2_15_55_1","first-page":"258","article-title":"AISI: a new disease severity assessment tool for hidradenitis Suppurativa","volume":"27","author":"Chiricozzi A","year":"2015","journal-title":"Wounds"},{"issue":"6","key":"e_1_2_15_56_1","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/jamadermatol.2023.0797","article-title":"Validation of the hidradenitis suppurativa investigator global assessment: a novel hidradenitis suppurativa\u2010specific investigator global assessment for use in interventional trials","volume":"159","author":"Garg A","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"3","key":"e_1_2_15_57_1","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/jamadermatol.2017.5890","article-title":"A novel severity assessment scoring system for hidradenitis Suppurativa supplemental content","volume":"154","author":"Hessam S","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"8","key":"e_1_2_15_58_1","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/jdv.16328","article-title":"Creation of a severity index for hidradenitis suppurativa that includes a validated quality\u2010of\u2010life measure: the HIDRAscore","volume":"34","author":"Marzano AV","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_15_59_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555\u20102513"},{"issue":"6","key":"e_1_2_15_60_1","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/bjd.21798","article-title":"Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the global VOICE project","volume":"187","author":"Midgette B","year":"2022","journal-title":"Br J Dermatol"},{"issue":"6","key":"e_1_2_15_61_1","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/bjd\/ljad069","article-title":"Factors associated with disease\u2010specific life impact in patients with hidradenitis suppurativa: results from the global VOICE project","volume":"188","author":"Garg A","year":"2023","journal-title":"Br J Dermatol"},{"issue":"9","key":"e_1_2_15_62_1","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/jdv.15519","article-title":"Quality of life measurement in hidradenitis suppurativa: position statement of the European academy of dermatology and venereology task forces on quality of life and patient\u2010oriented outcomes and acne, rosacea and hidradenitis suppurativa","volume":"33","author":"Chernyshov PV","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"e_1_2_15_63_1","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology life quality index (DLQI)\u2014a simple practical measure for routine clinical use","volume":"19","author":"Finlay AY","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"e_1_2_15_64_1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/bjd\/ljad079","article-title":"A systematic review of 454 randomized controlled trials using the dermatology life quality index: experience in 69 diseases and 43 countries","volume":"190","author":"Vyas J","year":"2024","journal-title":"Br J Dermatol"},{"issue":"1","key":"e_1_2_15_65_1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/jdv.15226","article-title":"Does the dermatology life quality index (DLQI) underestimate the disease\u2010specific burden of psoriasis patients?","volume":"33","author":"Langenbruch A","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"e_1_2_15_66_1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/ijd.16328","article-title":"A systematic review and meta\u2010analysis of sexual dysfunction in patients with hidradenitis suppurativa","volume":"62","author":"Varney P","year":"2023","journal-title":"Int J Dermatol"},{"issue":"2","key":"e_1_2_15_67_1","article-title":"Psychosocial implications and quality of life in patients with hidradenitis Suppurativa compared to those with atopic dermatitis and psoriasis: a cross\u2010sectional case\u2010control study","volume":"13","author":"Alya AS","year":"2023","journal-title":"Dermatol Pract Concept"},{"key":"e_1_2_15_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18435"},{"issue":"11","key":"e_1_2_15_69_1","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1111\/jdv.16642","article-title":"Validity of EQ\u20105D\u20105L, Skindex\u201016, DLQI and DLQI\u2010R in patients with hidradenitis suppurativa","volume":"34","author":"Gergely LH","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"e_1_2_15_70_1","doi-asserted-by":"crossref","first-page":"e484","DOI":"10.1111\/jdv.16398","article-title":"Dermatology life quality index (DLQI) score bands are applicable to DLQI\u2010relevant (DLQI\u2010R) scoring","volume":"34","author":"Rencz F","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"e_1_2_15_71_1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/bjd\/ljaf067","article-title":"Psychometric validation and interpretation thresholds of the hidradenitis suppurativa quality of life (HiSQOL\u00a9) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa","volume":"193","author":"Kirby JS","year":"2025","journal-title":"Br J Dermatol"},{"issue":"3","key":"e_1_2_15_72_1","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2025.5644","article-title":"Hidradenitis suppurativa patient\u2010reported outcome measures: a systematic review and meta\u2010analysis","volume":"162","author":"Tarafdar N","year":"2026","journal-title":"JAMA Dermatol"},{"issue":"2","key":"e_1_2_15_73_1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/bjd\/ljae367","article-title":"Validation of the real\u2010world application of the hidradenitis suppurativa quality of life (HiSQOL) score to adults with hidradenitis suppurativa","volume":"192","author":"Garg A","year":"2025","journal-title":"Br J Dermatol"},{"issue":"4","key":"e_1_2_15_74_1","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/bjd\/ljae486","article-title":"Minimal important difference of pain numeric rating scale in patients with hidradenitis suppurativa: results from THESEUS","volume":"192","author":"Pickles T","year":"2025","journal-title":"Br J Dermatol"},{"key":"e_1_2_15_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17306"},{"issue":"3","key":"e_1_2_15_76_1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/ijd.14706","article-title":"Work productivity and activity impairment in patients with hidradenitis suppurativa: a cross\u2010sectional study","volume":"59","author":"Yao Y","year":"2020","journal-title":"Int J Dermatol"},{"issue":"10","key":"e_1_2_15_77_1","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/ced\/llae120","article-title":"The impact of hidradenitis suppurativa on work productivity and performance: a systematic review and meta\u2010analysis","volume":"49","author":"Merchant SA","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"e_1_2_15_78_1","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v105.41298","article-title":"Development and validation of a disease\u2010specific outcomes tool for the assessment of patient benefits of treatment for hidradenitis Suppurativa: the PBI\u2010HS","volume":"105","author":"Kirsten N","year":"2025","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"e_1_2_15_79_1","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/bjd\/ljaf317","article-title":"The HIdradenitis suppurativa DrainagE (HIDE) scale: development and content validation of a patient reported outcome measure","volume":"193","author":"Thorlacius L","year":"2025","journal-title":"Br J Dermatol"},{"issue":"11","key":"e_1_2_15_80_1","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1001\/jamadermatol.2023.3282","article-title":"Outcome measures for the evaluation of treatment response in hidradenitis Suppurativa for clinical practice: a HiSTORIC consensus statement","volume":"159","author":"Mastacouris N","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"4","key":"e_1_2_15_81_1","doi-asserted-by":"crossref","DOI":"10.4081\/dr.2025.10124","article-title":"Ultrasound monitoring of hidradenitis suppurativa fistulas in treatment with adalimumab","volume":"17","author":"Caposiena Caro RD","year":"2025","journal-title":"Dermatol Reports"},{"issue":"1","key":"e_1_2_15_82_1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/jum.16351","article-title":"Update on ultrasound diagnostic criteria and new ultrasound severity and activity scorings of hidradenitis suppurativa: modified SOS\u2010HS and US\u2010HSA","volume":"43","author":"Wortsman X","year":"2024","journal-title":"J Ultrasound Med"},{"issue":"4","key":"e_1_2_15_83_1","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jaad.2016.05.009","article-title":"Color Doppler ultrasound assessment of morphology and types of fistulous tracts in hidradenitis suppurativa (HS)","volume":"75","author":"Wortsman X","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"e_1_2_15_84_1","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.20600","article-title":"International consensus statement on the use of ultrasound in hidradenitis suppurativa","volume":"40","author":"Wortsman X","year":"2026","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"e_1_2_15_85_1","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/jum.16635","article-title":"Enhancing hidradenitis suppurativa assessment: the role of ultra\u2010high frequency ultrasound in detecting microtunnels and refining disease staging","volume":"44","author":"Michelucci A","year":"2025","journal-title":"J Ultrasound Med"},{"issue":"2","key":"e_1_2_15_86_1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000495982","article-title":"Long\u2010wave medical infrared thermography: a clinical biomarker of inflammation in hidradenitis suppurativa\/acne inversa","volume":"235","author":"Zouboulis CC","year":"2019","journal-title":"Dermatology"},{"key":"e_1_2_15_87_1","doi-asserted-by":"crossref","unstructured":"Manzo MargiottaF KourtellariE MichelucciA RomanelliM DiniV ZouboulisCC.Combined thermography and ultrasound in hidradenitis suppurativa: a preliminary study.J Eur Acad Dermatol Venereol2026.","DOI":"10.1111\/jdv.70429"},{"issue":"3","key":"e_1_2_15_88_1","article-title":"Single\u2010cell sequencing reveals hippo signaling as a driver of fibrosis in hidradenitis suppurativa","volume":"134","author":"Straalen KR","year":"2024","journal-title":"J Clin Invest"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70635","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.70635","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70635","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:54:29Z","timestamp":1785509669000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.70635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":87,"alternative-id":["10.1111\/jdv.70635"],"URL":"https:\/\/doi.org\/10.1111\/jdv.70635","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"2026-06-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"jdv.70635"}}